Doxorubicin (Dox) is a secondary metabolite of the mutated strain of Streptomyces peucetius
var. Caesius and belongs to the anthracyclines family. The anti-cancer activity of Dox is …

Cardiotoxicity is one of the main adverse effects of chemotheraphy, affecting the completion
of cancer therapies and the short-and long-term quality of life. Anthracyclines are currently …

Nanomedicines for cancer treatment have been studied extensively over the last few
decades. Yet, only five anticancer nanomedicines have received approvals from the United …

The interest in non-coding RNAs, which started more than a decade ago, has still not
weakened. A wealth of experimental and clinical studies has suggested the potential of non …

Doxorubicin (DOX) is a kind of representative anthracyclines. It has greatly prolonged
lifespan of cancer patients. However, a long course of DOX chemotherapy could induce …

With the progression of tumor treatment, the 5-year survival rate of breast cancer is close to
90%. Cardiovascular toxicity caused by chemotherapy has become a vital factor affecting …

Purpose of review As cancer survivor rates improve with early screening and modern
treatment options, cardiotoxicity is becoming an increasing problem. It is imperative for …

Cardiotoxicity is the main side effect of several chemotherapeutic drugs. Doxorubicin (Doxo)
is one of the most used anthracyclines in the treatment of many tumors, but the development …

Simple Summary The effectiveness and safety of the anti-cancer agent doxorubicin
(anthracycline group medicine) depend on the metabolism and retention of the drug in the …

First isolated in the early 1960s, doxorubicin (DOX) is among the most effective anticancer
agents ever developed. DOX has been used mainly for the treatment of breast cancer, solid …